MK-677 (Ibutamoren): Evidence and Safety
MK-677 (ibutamoren, also written mk677 or mk 677) is an oral growth hormone secretagogue, not a peptide, that reliably raises growth hormone and IGF-1 by activating the ghrelin receptor. Merck ran it through Phase 2 human trials but never sought FDA approval, and the strongest completed trials found it failed to produce a meaningful clinical benefit for its most-marketed uses, including a placebo-controlled Alzheimer's trial that found no effect on disease progression despite raising IGF-1. It is not a legal dietary supplement, it is banned at all times in Olympic sport, and Merck's own data documented real side effects, including increased appetite, fluid retention and reduced insulin sensitivity, information worth reviewing with a clinician before considering it.
Understand what's actually being sold Technically not a peptide: an orally active small-molecule ghrelin-receptor agonist, popular because it's a pill rather than an injection, but stimulating the same growth-hormone and IGF-1 release pathway as injectable secretagogues.
This distinction matters for anyone assuming “peptide” marketing claims automatically apply to MK-677's chemistry.
See what Merck's own trials actually found Merck ran Phase 2 human trials for growth-hormone deficiency and hip-fracture recovery and frailty, but never submitted MK-677 for FDA approval. There is no completed RCT supporting its popular use (muscle gain, sleep, anti-aging) in healthy adults.
Real trials existing is not the same as those trials proving the popular use case works.
Know where it actually stands Not FDA-approved for any indication, not DEA-scheduled. Capsules marketed as “MK-677 supplements” are themselves illegal unapproved-drug marketing, not legal dietary supplements. A reported removal from the FDA's Category 2 list (around April 2026) is unconfirmed pending review. Banned at all times under WADA's S2 category.
“Sold as a supplement” does not make MK-677 a legal dietary supplement under FDA's framework.
Know the real, trial-documented risk Merck's own trials documented a significant increase in appetite (the basis of the frailty-trial interest) and fluid retention or edema and increased blood glucose or reduced insulin sensitivity at the doses tested. These are real, trial-derived safety signals. Unregulated-manufacturing purity risk applies to the consumer product sold online.
These signals come from Merck's own data, not from anecdote, and should be stated plainly rather than minimized.
Merck developed MK-677 and ran Phase 2 human trials, for growth-hormone deficiency and for a hip-fracture-recovery and frailty population, but never completed the process to submit it for FDA approval.
View sources
Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (GH-secretagogue class segment, includes MK-677)
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone considering MK-677 who wants the honest evidence before discussing it with a clinician
- Athletes checking WADA and anti-doping status
- Readers who assumed “MK-677 supplement” meant it was a legal dietary supplement
- Readers comparing oral GH secretagogues to FDA-approved GH-axis drugs like tesamorelin
Cautions
- Not FDA-approved for any indication; capsules marketed as “supplements” are themselves unapproved-drug marketing under FDA's framework.
- Banned at all times under WADA's anti-doping code (S2); can result in a competition ban if detected.
- Merck's own Phase 2 trials documented increased appetite and reduced insulin sensitivity as real safety signals.
- Educational only, not medical advice.